Colonial Trust Advisors cut its stake in C.R. Bard, Inc. (NYSE:BCR) by 1.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,050 shares of the medical instruments supplier’s stock after selling 200 shares during the quarter. Colonial Trust Advisors’ holdings in C.R. Bard were worth $3,493,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Leucadia National Corp purchased a new stake in shares of C.R. Bard during the second quarter worth about $13,184,000. Vivaldi Asset Management LLC purchased a new stake in shares of C.R. Bard during the second quarter worth about $57,965,000. Credit Agricole S A increased its position in shares of C.R. Bard by 2.8% during the first quarter. Credit Agricole S A now owns 89,102 shares of the medical instruments supplier’s stock worth $22,148,000 after acquiring an additional 2,425 shares during the last quarter. Sirios Capital Management L P purchased a new stake in shares of C.R. Bard during the second quarter worth about $71,393,000. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in shares of C.R. Bard by 12.3% during the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 16,951 shares of the medical instruments supplier’s stock worth $5,358,000 after acquiring an additional 1,859 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors.

C.R. Bard, Inc. (NYSE BCR) traded up 0.19% during trading on Thursday, reaching $320.66. The company had a trading volume of 62,189 shares. The firm has a 50-day moving average price of $319.90 and a 200 day moving average price of $304.42. The stock has a market cap of $23.30 billion, a P/E ratio of 42.10 and a beta of 0.58. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $324.58.

C.R. Bard (NYSE:BCR) last released its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. The firm had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.54 EPS. Equities research analysts predict that C.R. Bard, Inc. will post $11.81 EPS for the current fiscal year.

WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/05/colonial-trust-advisors-cuts-holdings-in-c-r-bard-inc-bcr.html.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the transaction, the insider now owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Sharon M. Luboff sold 30,252 shares of the company’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $320.00, for a total transaction of $9,680,640.00. The disclosure for this sale can be found here. 0.80% of the stock is owned by insiders.

A number of brokerages have recently issued reports on BCR. Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. BidaskClub lowered C.R. Bard from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a strong buy rating to the company’s stock. C.R. Bard presently has an average rating of “Hold” and a consensus target price of $292.00.

C.R. Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.